Jessica Matthews raises awareness of deadly cancer outcomes for Black people while sharing intimate moments, losing her hair ...

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) has announced the resumption of patient enrollment in a Phase 1/2 clinical trial evaluating seclidemstat combined with azacitidine for myelodysplastic ...

Meetings designed to distribute grant money to fund research were canceled as part of a communications freeze at health ...

A novel approach developed by scientists, including Rice University chemist James Tour, could transform treatment for ...

MD Anderson Cancer Center named Artemio Mier associate vice president of revenue cycle, patient business services.

HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and ... Genetics and the clinical and translational research expertise of MD ...

“That’s quite an accomplishment,” says Allison, professor and chair of immunology at The University of Texas MD Anderson Cancer Center ... translated into clinical trials and beyond.” ...

A phase 2 trial finds that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy.

Forbes does not accept payment for placement on lists. This company paid for expanded information and features to appear on their Forbes Profile. For more information, click here. From MD Anderson ...

Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response ...

HOUSTON--(BUSINESS WIRE)--ImmunoMet Therapeutics, Inc., (“ImmunoMet”, or the “Company”), a clinical stage biotechnology company committed to giving patients a novel approach to fight cancer, today ...